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Abstract 
 
Objective 
Elevated white blood cell count (WBC) is associated with a higher risk of cardiovascular 
disease (CVD). We aimed to investigate whether specific leukocyte subpopulations, which 
may more closely indicate a specific inflammatory pathway, are specifically associated with 
CVD. 
Approach and results  
478,259 participants from UK Biobank with data for WBC were included. Death due to CVD 
(n=1377), and non-CVD causes (n=8987) occurred during median follow up time of 7.0 
years (IQR 6.3-7.6). In Cox models deciles of leukocyte counts (lymphocytes, monocytes, 
neutrophils, eosinophils and basophils) were examined using the 5th decile as the referent 
group. Models were stratified by sex and adjusted for a range of classical risk factors.  A 
sensitivity analysis excluded participants with baseline comorbidites and the first 2 years of 
follow-up. Men (HR 1.59; 95%CI 1.22-2.08) and women (HR 2.15; 1.38-3.35) in the highest 
decile of neutrophil count were at higher risk of CVD mortality and non-fatal CVD (Men HR 
1.28; 95% CI 1.16-1.42 and women HR 1.21; 95% CI 1.06-1.38). In the sensitivity analysis 
the power to investigate CVD mortality was limited, but for both sexes combined the linear 
HRs for a 1*109/L cell count increase in WBC and neutrophils respectively was 1.05 (1.03-
1.07) and 1.07 (1.04-1.11). 
Conclusions 
Among circulating leukocyte subpopulations, neutrophil count in men was most consistently 
associated with fatal and non-fatal CVD.  Further studies of interventions that lower 
circulating neutrophils, such as canakinumab, are required to investigate causality. 
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CKD: Chronic kidney disease 
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Introduction 
Inflammation may be a key, potentially modifiable, process in the development of 
cardiovascular disease (CVD) 1,2. Elevated levels of inflammatory mediators within healthy 
people may increase the risk of CVD. Many studies have reported that a range of different 
blood-based inflammatory biomarkers are associated with an increased risk of incident CVD 
events 3–7. This initially led to an interest in reducing the risk of CVD by targeting patients 
with evidence of inflammation as illustrated by high sensitivity C-reactive protein 8. More 
recently, with genetic evidence supporting interleukin-6 pathway as causal in the 
development of CVD 9, interest has emerged in directly inhibiting specific parts of the 
inflammatory pathway to prevent CVD 10,11. 
 
One of the simplest, and most commonly measured markers of the immune response and 
inflammation, is the total white blood cell (WBC) count. A number of studies have reported 
that an elevated WBC is associated with higher rates of incident CVD 12–15 and non-CVD 
mortality 13,16. The association between elevated WBC and elevated CVD risk may indicate 
that infection and inflammation are part of the pathway leading to the development of CVD. 
However, WBC may also reflect poor health and risk of death from any cause, and therefore 
be a non-specific association. 
 
Different subpopulations of WBC (lymphocytes, neutrophils, monocytes, eosinophils and 
basophils) may also be associated with CVD and non-CVD mortality 14,17,18 . In particular, 
elevated neutrophil counts may be associated with a higher risk of CVD in routine population 
datasets 18, although the influence of clinical susceptibility bias is difficult to account for in 
such databases, and the influence of reverse causality requires consideration 19. An 
additional consideration is that different associations in specific cell types may be suggestive 
of distinct pathways that lead to CVD. While neutrophils (granulocytes that comprise the 
majority of circulating WBCs) can cause tissue damage, including in the walls of blood 
vessels via the formation of neutrophil extracellular traps (NETs) 20 which in turn lead to 
macrophage-produced interleukin precursors 21, other white cell types such as monocytes 
(precursors of tissue macrophages) may also be important 22. 
 
To explore these associations further we examined the association between WBC and the 
differential leukocyte counts with all-cause mortality, CVD mortality, and non-CVD mortality 
in the UK Biobank population. This is a large population-based cohort study with > 500,000 
participants that have no clinical indication for WBC measurement. Simultaneous 
comparison of differential counts with both CVD and non-CVD mortality allows specificity of 
the associations to be investigated. To restrict the potential for reverse casualty - i.e. 
whereby pre-existing and subclinical illness might cause changes in leukocyte counts - we 
also examined these associations in a sensitivity analysis.  
 
Materials and Methods 
UK Biobank recruited 502,655 participants (aged 37 to 73) from 22 assessment centres 
across the UK between April 2007 and December 2010 23. Baseline biological 
measurements were recorded and touch-screen questionnaires were administered, as 
described elsewhere 1,2. UK Biobank received ethical approval from the North West Multi-
centre Research Ethics Committee (REC reference: 11/NW/03820). All participants gave 
written informed consent before enrolment in the study, which was conducted in accord with 
the principles of the Declaration of Helsinki. 
 
Smoking status was categorised into never, former or current smoking. Ethnicity was coded 
as white, South Asian, black, or mixed/other, with white as the referent group. Body mass 
index (BMI) was calculated as (weight (kg) /height2 (m)). Area-based socioeconomic status 
was derived from postcode of residence, using the Townsend score 3. White blood cell 
counts were measured on fresh samples as an absolute number per unit volume, and their 
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component leukocytes (lymphocytes, monocytes, neutrophils, eosinophils, and basophils) as 
absolute measures and proportions of the overall WBC; all using an automated, clinically 
validated, Coulter LH 750. Calibration and quality control were performed in line with the 
manufacturer’s recommendations. Further details of these measurements can be found in 
the UK Biobank online showcase and protocol (http://www.ukbiobank.ac.uk).  
 
Specific baseline comorbidities of interest were self-reported CVD (myocardial infraction, 
angina, stroke or transient ischaemic attack), diabetes, rheumatoid arthritis, chronic kidney 
disease (CKD), and atrial fibrillation or flutter. A category of “other baseline comorbidities” 
potentially associated with inflammation was defined as any of self-reported baseline 
diagnosis of; peripheral vascular disease, heart failure, any malignancy, dementia, 
Parkinson’s disease, psoriasis or eczema, osteoporosis, polyarthropathies and systemic 
connective tissue disorders (other than rheumatoid arthritis), multiple sclerosis, chronic 
fatigue syndrome, chronic liver disease, endometriosis, polycystic ovarian syndrome, 
diverticular disease of the intestine, hypertension, depression, painful conditions, asthma, 
treated dyspepsia, thyroid disorders, chronic obstructive pulmonary disorder, inflammatory 
bowel disease or irritable bowel syndrome, alcohol problems, other psychoactive substance 
abuse, treated constipation, prostate disorders, glaucoma, epilepsy, migraines, chronic 
sinusitis, anorexia or bulimia, anxiety and other neurotic or stress related disorders, 
schizophrenia, viral hepatitis, bronchiectasis, Ménière's disease, and pernicious anaemia.  
 
Date and cause of death were obtained from death certificates held by the National Health 
Service (NHS) Information Centre for participants from England and Wales and the NHS 
Central Register Scotland for participants from Scotland. There were three outcomes of 
interest in the current study; all-cause mortality, death related to CVD (primary cause of 
death including ICD-10 codes I20-I23, I24.1, I25.2 and I60-I64) and death unrelated to CVD 
(any ICD-10 codes excluding I00-I99). We also examined the association between WBC and 
non-fatal CVD outcomes. Non-fatal outcomes (codes I20-I23, I24.1, I25.2 and I60-I64) were 
ascertained from hospitalisation records using record linkage to national hospitalisation data. 
End of follow-up for the main study for each participant was recorded as the date of death or 
the date of end of follow-up for the assessment centre attended (30/11/2015 for Scottish 
centres, 31/01/2016 for English or Welsh centres), whichever came first. End of follow-up for 
the nonfatal events analysis was the date of admission of the first CVD hospitalisation, or the 
date of end of follow-up for the assessment centre attended, or the date of death, whichever 
came first. The period at risk per participant began on the date of their assessment.  
Participants who were hospitalised within 30 days of their assessment were excluded. 
 
Statistical analyses 
The distribution of classical risk factors (age, sex, systolic blood pressure (SBP), BMI, 
deprivation score, smoking, ethnicity, baseline CVD, baseline diabetes, family history of CVD 
(mother, father or sibling), rheumatoid arthritis, CKD (stage 4 or 5), atrial fibrillation, and 
other baseline illness), and leukocyte subpopulations, were investigated by decile of WBCs. 
We examined the relationship between WBC and its constituents and the outcomes using 
restricted cubic splines of each cell count restricted to values of their mean +/- 4 standard 
deviations, and found that the deciles adequately modelled the data (Figs sVII-sXXIV). We 
present the primary results on the basis of deciles.  Classical risk factors were expressed as 
mean (standard deviation) if symmetrically distributed, median (interquartile range) if 
skewed, and number (%) if categorical. Tests for trends across WBC deciles were performed 
using regression, a Wilcoxon test for trend, or a chi-squared test, respectively. Associations 
between classical risk factors, WBC, and leukocyte subpopulations with mortality outcomes 
were also tabulated using these methods. Correlations between WBC and its components 
were tested by Spearman correlation coefficients.  
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Associations of leukocytes with all-cause mortality, CVD mortality, and non-CVD mortality 
were investigated using Cox-proportional hazard models. WBC and leukocyte counts at 
baseline were entered into the model as absolute counts, by sex-specific deciles. The fifth 
decile was used as the referent group. The adjusted model included continuous terms for 
age, deprivation index, systolic blood pressure and BMI and categorical variables for 
smoking, ethnicity, diabetes, family history of CVD, rheumatoid arthritis, atrial fibrillation, 
baseline CVD, and the binary composite variable for other baseline comorbidities (defined 
above). The results were reported as sex-specific hazard ratios for deciles of the leukocytes, 
together with 95% confidence intervals. We also investigated associations of leukocytes with 
outcomes using the exposure as a linear variable where this was an appropriate model fit. 
To examine the potential role of reverse causality, a sensitivity analysis was performed that 
excluded those with any baseline comorbidities (diabetes, rheumatoid arthritis, atrial 
fibrillation, baseline CVD, and other baseline illness) and, the first 2 years of follow-up. The 
results from this analysis had lower power; so only linear models combining sexes are 
presented. A further sensitivity analysis was conducted using a Fine and Gray model to 
adjust CVD mortality for the competing risk of non-CVD mortality (and vice-versa) 4. These 
models did not meaningfully change hazard ratios, and so the more complex competing risk 
model was not utilised.  We tested the interaction between smoking status and WBC and its 
components for CV mortality and found no significant interactions after adjusting for multiple 
testing.   
 
All analyses were performed using STATA 14 (StataCorp LP). A p-value of <0.05 was 
considered statistically significant.  
 
Results 
Cross sectional associations 
Of 502,634 people included in the study, WBC data was available in 478,279 (95.2%), 
lymphocytes, monocytes, neutrophils, eosinophils and basophils in 477,401 (95.0%). There 
were 258,966 women and 219,313 men with WBC measured. 
 
Participants with higher WBC count were generally older, had higher systolic BP, higher BMI 
and were more likely to be a smoker, have a family history of CVD, and have baseline 
rheumatoid arthritis, chronic kidney disease, diabetes, CVD, atrial fibrillation, or other 
comorbidities (Table 1). A higher proportion of South Asians and a lower proportion of black 
ethnicities were observed in high WBC deciles. Deprivation scores were higher in the 
extreme deciles of WBC, particularly the lowest decile. The proportion of cells that are 
components of WBC varied by WBC count; proportions of neutrophils increased 
substantially as deciles of WBC increased, proportions of lymphocytes and monocytes fell, 
whereas proportions of eosinophils and basophils remained broadly similar. 
 
In correlations of leukocyte counts with each other (Table 2), higher WBC counts were 
driven by higher absolute numbers of every differential leukocyte count, with the correlation 
being particularly high for neutrophils (r=0.90). Only neutrophil percentage was positively 
associated with WBC, whereas every other leukocyte percentages had an inverse 
association with WBCs. Percentage of neutrophils was strongly inversely associated with 
percentage of lymphocytes (r=-0.92). 
 
Univariable association of leukocytes with mortality 
Among participants with a WBC measurement, median follow up time for all cause mortality 
was 7.0 years (IQR 6.3-7.6). All cause mortality occurred in 5255 women (2.0%) and 8227 
men (3.8%) in the full analysis, and in 753 women (0.9%) and 1146 (1.5%) men in the 
sensitivity analysis. CVD mortality occurred in 428 women (0.2%) and 949 men (0.4%) in the 
full analysis, and in 50 women (0.1%) and 107 (0.1%) men in the sensitivity analysis. Non-
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CVD mortality occurred in 3982 women (1.5%) and 5005 men (2.3%) in the in the full 
analysis, and in 626 women (0.7%) and 814 (1.1%) men in the sensitivity analysis. 
 
Death from any cause as well as CVD causes was generally associated with a more adverse 
clinical risk profile (Table 3), including older age, male sex, higher SBP, higher BMI, 
smoking, baseline CVD, diabetes, rheumatoid arthritis, CKD, atrial fibrillation and other 
baseline illness. The group who died from CVD or non-CVD causes during follow-up 
generally also had a lower lymphocyte count and lymphocyte proportion at baseline. In 
contrast, those who died from CVD or non-CVD causes during follow-up generally had 
slightly higher monocyte count and proportion of monocytes, and a substantially higher 
neutrophil count and proportion of neutrophils. The group who died from CVD or non-CVD 
causes also had a slightly higher eosinophil and basophil counts.  
 
Multivariable association of leukocytes with all cause mortality 
In adjusted Cox models, total WBC, neutrophils, basophils and monocytes showed generally 
J-shaped associations with all cause mortality in both sexes (Fig A-D). However, in the 
sensitivity analysis, these associations were generally attenuated to approximately more 
linear forms. For both sexes combined the linear HRs for a 1*109/L cell count increase in 
WBC and neutrophils respectively was 1.06 (1.05-1.07) and 1.10 (1.07-1.12) respectively. 
Data were similar excluding smokers. For lymphocytes, those with low levels tended to be at 
far higher risk of all cause mortality than those with elevated levels (Fig D). The sensitivity 
analysis attenuated this towards the null (Table II). 
 
Multivariable association of leukocytes with CVD mortality 
Men in the highest decile of WBC were at greater risk of CVD mortality compared to those in 
the fifth decile (HR 1.64; 95% CI 1.24-2.16).  Both men (HR 1.59; 1.22-2.08) and women 
(HR 2.15; 95% CI 1.38-3.35) in the highest decile of neutrophil count were at greater risk of 
CVD mortality. Monocyte count was also associated with CVD mortality in men (HR 1.57; 
95% CI 1.26-1.97).   For both sexes combined the linear HRs for a 1*109/L cell count 
increase in WBC and neutrophils respectively was 1.04 (0.97-1.11) and 1.05 (0.94-1.17) 
respectively.  
 
Multivariable association of leukocytes with non-CVD mortality 
U-shaped associations were found between deciles of monocytes, neutrophils, WBC and 
basophils with non-CVD mortality. For WBCs and neutrophils, these associations were 
attenuated in the sensitivity analysis. For both sexes combined the linear HRs for a 1*109/L 
cell count increase in WBC and neutrophils respectively was 1.06 (1.04-1.07) and 1.10 
(1.071.13) respectively.  
 
Multivariable association of leukocytes with nonfatal CVD 
Associations between leukocyte deciles and non-fatal CVD were similar to, but generally 
less strong than, those with CVD mortality. Men (HR 1.28; 95% CI 1.16-1.42) and women 
(HR 1.21; 95% CI 1.06-1.38) in the highest decile of WBC were at greater risk of non-fatal 
CVD compared to those in the fifth decile (Table V). This trend was also true of neutrophils, 
and of monocytes among men.  For both sexes combined the linear HRs for a 1*109/L cell 
count increase in WBC and neutrophils respectively was 1.05 (1.03-1.07) and 1.07 (1.04-
1.11) respectively. Most associations were removed in the sensitivity analysis, with the 
exception of high monocytes in women and low basophils in both sexes, which retained a 
higher risk of nonfatal CVD events. 
 
Discussion 
In this large, prospectively enrolled cohort of over 475,000 individuals from a general 
population, we found that a high WBC is associated with both CVD and non-CVD mortality, 
consistent with prior studies 12–15. In addition we report that the leukocyte subpopulations are 
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differentially associated with CVD mortality and non-fatal CVD.  Specifically we found that 
higher counts of neutrophils are associated with a higher risk of CVD mortality and non-fatal 
CVD, in line with previous data 14,17,18. Our data emphasise the importance of reverse 
causality in influencing the association between differential blood counts and outcomes.  
Therefore, additionally, we have shown that the association of neutrophils with non-fatal 
CVD remains robust to a sensitivity analysis that attempts to limit the influence of reverse 
causality. We could not confirm this for fatal CVD, primarily due to lack of power. The distinct 
association of neutrophils with CVD is of particular interest given that inhibiting the IL-1 
pathway with canakinumab substantially reduces circulating neutrophil counts 23,24 and has 
been shown to prevent CVD25. 
 
Our a priori hypothesis was that a specific leukocyte population might be more specifically 
associated with CVD mortality, in line with observations that neutrophils, macrophages, or 
lymphocytes might play a specific role in the immune response that causes, and results 
from, atherosclerosis 19,21,29-31. In contrast to prior studies we simultaneously examined not 
only the association between WBC and mortality outcomes, but also subpopulations of 
leukocytes. Recent data from a large cohort study has shown that WBC was associated with 
CHD and cancer mortality among healthy women, even after excluding those with 
comorbidities (cardiovascular diseases, connective tissue disease, ulcerative colitis, liver 
disease, diabetes, or cancers) and early deaths during follow-up 13. The association of WBC 
with CVD mortality among women in UK Biobank was fairly weak, but the association of 
neutrophils with CVD we report was strong in both sexes, and is also similar to a recent 
large cohort study 18. Our sensitivity analysis attenuated associations of circulating leukocyte 
counts with mortality outcomes. This suggests an element of reverse causality 19. 
Mechanisms that explain this observation likely include the association between neutrophilia 
and trauma, stress, bacterial infection, smoking, and indolent cancer 26; any of which 
ultimately might increase the risk of death from any cause. Likewise, lymphopenia is likely to 
be caused by old age, viral infection, autoimmune disease, renal failure and 
immunosuppressive drugs 27. By excluding those with a range of baseline diseases, and 
those who develop disease within 2 years of baseline, the present results provide models 
that limit the effect of baseline disease on counts themselves.  
 
 
What mechanisms might explain the association of leukocytes with CVD mortality? The 
inflammatory hypothesis of CVD is well established 28. Underpinning this, cellular 
atherosclerotic plaques appear more prone to rupture 32. It is hypothesised that leukocytes 
may play a direct role in destabilising the plaque itself 34, 33 through fibrous cap thinning, 
although it may be that circulating levels of leukocytes do not necessarily reflect resident 
cells within atherosclerotic plaques.  Investigating specific differential counts, our data 
suggest that high circulating neutrophil levels are linearly associated with CVD mortality that 
occurs beyond a 2 year time horizon in ostensibly healthy people. The same does not 
appear to be true of other leukocytes. It is interesting that, until recently, neutrophils were a 
neglected leukocyte in atherosclerosis research. There are clear mechanisms that might 
explain why neutrophils might play an important role in causing CVD death 35. Neutrophils 
interact with cholesterol crystals to produce pro- IL-120 They can form structures that bind 
bacteria and platelets, the end result of which is that neutrophils release nuclear material 
leading to cell death and thrombosis 37.  Neutrophils are, therefore, intimately linked to the 
inflammatory cascade, which can be promoted through a pro-atherogenic environment. 
Other environmental factors, such as smoking 36, might also promote neutrophilia and CVD 
death, resulting in confounding. However, our sensitivity analysis suggests there may be an 
independent association too. Inhibiting IL-1 in patients with established CVD reduces 
cardiovascular events 10,25, and strongly reduces circulating neutrophil counts 29,30. Our 
findings suggest that further work should be done in patients without pre-existing CVD to 
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determine if IL-1 blockers, or other modulators of the immune response to inflammation, 
may have a role to play in the prevention of CVD, and the role of neutrophils in this context.   
 
Higher neutrophil counts were also associated with a higher risk of non-CVD death. Here the 
association may be even more complex. Specific non-CVD conditions may be linked to 
higher neutrophil counts through different pathways. For instance, there is evidence that 
people with chronic inflammatory conditions such as RA have increased risk of death 
beyond that cause by CVD (http://onlinelibrary.wiley.com/doi/10.1002/acr.22752/abstract). 
 There has also been speculation that tumor-infiltrating neutrophils may be important in the 
prognosis of several types of cancer 
(https://www.sciencedirect.com/science/article/pii/S1044579X13000138). As noted above, 
mechanisms that may underlie the associations we observe include the influence of indolent 
malignancy (both solid organ and haematological) and other confounders such as 
inflammatory diseases and smoking. While we corrected for as many of these as possible 
through multivariable analysis and sensitivity analysis there remains a significant element of 
confounding and reverse causality. More work is required to examine the association 
between neutrophils and specific non-CVD causes of death to determine potential 
mechanisms underlying our findings. 
 
Our study has a number of strengths. The UK Biobank includes a wide sample of the UK 
general population in terms of age, sex, ethnicity and socioeconomic status, and as such is 
not derived from health records of patients with a clinical indication for leucocyte 
measurement, in contrast to prior work 18. Further strengths of the study include its large 
sample size, comprehensive phenotyping, and simultaneous consideration of differential 
leukocyte counts derived from a central laboratory measurement, also in contrast to prior 
work 18. The side-by-side comparison of CVD and non-CVD mortality gives an indication of 
the specificity of associations, although we did not further subdivide non-CVD morality due to 
lack of adjudicated outcomes. It is notable that inflammatory markers appear to have a 
stronger association with CVD mortality than with non-fatal events 38,39. Weaknesses include 
the lack of data to adjust for lipids, although the extensive adjustment model will capture 
much of this confounding by proxy. Lack of adjustment for medication is a further limitation, 
although again adjustment for co-morbidity accounts for much of the association. Reverse 
causality is possible in any observational study, and whilst our results include a sensitivity 
analysis and an analysis excluding those with diagnosed co-morbidities, we cannot exclude 
the potential of further reverse causality explaining some of the associations that we report.  
 
In conclusion, we report that among leukocytes higher neutrophil count is particularly 
associated with higher CVD risk in a general population. This association appears to be 
robust in those without comorbidity at baseline or in those who may have unrecognised 
disease at baseline. Further work is required to determine if modulation of the immune 
responses that involve neutrophils, via canakinumab or other interventions, can lead to a 
reduction in CVD mortality. 
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Highlights 
 Among circulating leukocyte subpopulations, neutrophil count was most strongly, and 
linearly, associated with higher CVD mortality. 
 Data were robust to a sensitivity analysis excluding those with pre-existing 
comorbidities and the first 2 years of follow-up. 
 Circulating lymphocytes showed trends towards an inverse association with CVD 
mortality. 
 Leukocyte subpopulations also showed similar associations with non-CVD mortality 
 
Figure Legends 
Figure A 
Association of deciles of WBC with three mortality outcomes (A all-cause mortality, B fatal 
CVD, C non-CVD mortality) in all study participants, stratified by sex (blue= male, 
red=female).  
 
Figure B 
 
Association of deciles of neutrophil count with three mortality outcomes in all study 
participants (A all-cause mortality, B fatal CVD, C non-CVD mortality), stratified by sex 
(blue= male, red=female). 
 
Figure C 
 
Association of deciles of monocyte count in all study participants with three mortality 
outcomes (A all-cause mortality, B fatal CVD, C non-CVD mortality), stratified by sex (blue= 
male, red=female). 
 
Figure D 
 
Association of deciles of lymphocyte count in all study participants with three mortality 
outcomes (A all-cause mortality, B fatal CVD, C non-CVD mortality), stratified by sex (blue= 
male, red=female). 
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Table 1 Association of WBC count (by deciles) with classical risk factors 
≤4.87 
(109/L) 
4.87-5.41 
(109/L) 
5.41-5.88 
(109/L) 
5.88-6.29 
(109/L) 
6.29-6.69 
(109/L) 
6.69-7.10 
(109/L) 
7.10-7.60 
(109/L) 
7.60-8.20 
(109/L) 
8.20-9.18 
(109/L) 
≥9.18 
(109/L) 
P-value for 
trend 
n=48057 n=49251 n=46659 n=47508 n=47873 n=51802 n=44149 n=49550 n=45775 n=47635 
Age (years) 55.5 ± 7.9 56.2 ± 7.9 56.5 ± 8.0 56.7 ± 8.0 56.7 ± 8.0 56.9 ± 8.1 56.9 ± 8.1 56.8 ± 8.2 56.8 ± 8.2 56.6 ± 8.3 <0.0001 
Male sex 
21299 
(44.3%) 
22316 
(45.3%) 
21341 
(45.7%) 
21660 
(45.6%) 
21936 
(45.8%) 
23891 
(46.1%) 
20361 
(46.1%) 
22813 
(46.0%) 
21393 
(46.7%) 
22299 
(46.8%) <0.001 
SBP (mmHg)   
136.1 ± 
19.1 
137.8 ± 
19.4 
138.8 ± 
19.5 
139.4 ± 
19.5 
139.9 ± 
19.7 
140.5 ± 
19.6 
140.8 ± 
19.8 
141.3 ± 
19.7 
141.6 ± 
19.8 
141.8 ± 
19.84 <0.0001 
BMI (kg/m2) 25.8 ± 4.1 26.4 ± 4.1 26.7 ± 4.3 27.0 ± 4.4 27.2 ± 4.5 27.6 ± 4.6 27.8 ± 4.8 28.1 ± 5.0 28.5 ± 5.2 29.0 ± 5.8 <0.0001 
Deprivation 
(score) -1.4 ± 3.1 -1.5 ± 3.0 -1.5 ± 3.0 -1.5 ± 3.0 -1.5 ± 3.0 -1.4 ± 3.0 -1.3 ± 3.1 -1.3 ± 3.1 -1.1 ± 3.2 -0.6 ± 3.3 <0.0001 
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Smoking 
Never 
30236 
(63.0%) 
29896 
(60.8%) 
27647 
(59.3%) 
27703 
(58.4%) 
27413 
(57.3%) 
28737 
(55.5%) 
23886 
(54.1%) 
25599 
(51.7%) 
21999 
(48.1%) 
19188 
(40.3%) <0.0001 
Previous 
15810 
(32.9%) 
16980 
(34.5%) 
16406 
(35.2%) 
16785 
(35.4%) 
17003 
(35.5%) 
18492 
(35.7%) 
15792 
(35.8%) 
17635 
(35.6%) 
15789 
(34.5%) 
14607 
(30.7%) 
Current 
1962 
(4.1%) 
2331 
(4.7%) 
2550 
(5.5%) 
2966 
(6.3%) 
3418 
(7.1%) 
4509 
(8.7%) 
4437 
(10.1%) 
6257 
(12.6%) 
7937 
(17.4%) 
13792 
(29.0%) 
Ethnicity 
White 
42762 
(89.4%) 
45109 
(92.0%) 
42803 
(92.2%) 
43736 
(92.5%) 
44339 
(93.0%) 
47787 
(92.7%) 
40657 
(92.5%) 
45635 
(92.5%) 
41976 
(92.1%) 
43503 
(91.8%) <0.0001 
South Asian 
344 
(0.7%) 491 (1.0%) 568 (1.2%) 657 (1.4%) 676 (1.4%) 871 (1.7%) 811 (1.8%) 972 (2.0%) 
1014 
(2.2%) 
1090 
(2.3%) 
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Black 
2291 
(4.8%) 
1148 
(2.3%) 833 (1.8%) 727 (1.5%) 518 (1.1%) 517 (1.0%) 391 (0.9%) 354 (0.7%) 322 (0.7%) 
302 
(0.6%) 
Other 
2421 
(5.1%) 
2302 
(4.7%) 
2216 
(4.8%) 
2150 
(4.5%) 
2132 
(4.5%) 
2382 
(4.6%) 
2105 
(4.8%) 
2363 
(4.8%) 
2260 
(5.0%) 
2490 
(5.3%) 
Baseline CVD 
1602 
(3.3%) 
1947 
(4.0%) 
2168 
(4.6%) 
2288 
(4.8%) 
2620 
(5.5%) 
3154 
(6.1%) 
2854 
(6.5%) 
3475 
(7.0%) 
3736 
(8.2%) 
4667 
(9.8%) <0.0001 
Baseline 
diabetes 
1355 
(2.8%) 
1439 
(2.9%) 
1586 
(3.4%) 
1810 
(3.8%) 
2071 
(4.3%) 
2571 
(5.0%) 
2463 
(5.6%) 
3138 
(6.3%) 
3594 
(7.9%) 
4951 
(10.4%) <0.0001 
Family history 
of CVD 
25871 
(53.8%) 
27311 
(55.5%) 
26058 
(55.8%) 
26961 
(56.8%) 
27115 
(56.6%) 
29289 
(56.5%) 
25119 
(56.9%) 
28398 
(57.3%) 
26108 
(57.0%) 
27249 
(57.2%) <0.0001 
Rheumatoid 
arthritis 
499 
(1.0%) 473 (1.0%) 479 (1.0%) 538 (1.1%) 470 (1.0%) 492 (0.9%) 469 (1.1%) 580 (1.2%) 574 (1.3%) 
778 
(1.6%) <0.0001 
Baseline CKD 53 (0.1%) 56 (0.1%) 63 (0.1%) 53 (0.1%) 73 (0.2%) 88 (0.2%) 77 (0.2%) 93 (0.2%) 101 (0.2%) 
163 
(0.3%) <0.0001 
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Atrial fibrillation 
260 
(0.5%) 313 (0.6%) 282 (0.6%) 328 (0.7%) 355 (0.7%) 413 (0.8%) 350 (0.8%) 398 (0.8%) 414 (0.9%) 
449 
(0.9%) <0.0001 
Other baseline 
illness 
27858 
(58.0%) 
29319 
(59.5%) 
28548 
(61.2%) 
29514 
(62.1%) 
30219 
(63.1%) 
33581 
(64.8%) 
29096 
(65.9%) 
33222 
(67.0%) 
31629 
(69.1%) 
34511 
(72.4%) <0.0001 
Lymphocyte 
Count  
1.4 [1.1, 
1.6] 
1.6 [1.3, 
1.8] 
1.7 [1.4, 
2.0] 
1.8 [1.5, 
2.1] 
1.9 [1.6, 
2.3] 
2.0 [1.6, 
2.3] 
2.0 [1.7, 
2.4] 
2.1 [1.8, 
2.5] 
2.3 [1.9, 
2.7] 
2.5 [2.1, 
3.1] <0.0001 
Monocyte 
Count   
0.3 [0.3, 
0.4] 
0.4 [0.3, 
0.5] 
0.4 [0.3, 
0.5] 
0.4 [0.3, 
0.5] 
0.4 [0.4, 
0.5] 
0.5 [0.4, 
0.6] 
0.5 [0.4, 
0.6] 
0.5 [0.4, 
0.6] 
0.6 [0.4, 
0.7] 
0.6 [0.5, 
0.8] <0.0001 
Neutrophil 
Count   
2.5 [2.1, 
2.8] 
3.0 [2.7, 
3.3] 
3.4 [3.1, 
3.6] 
3.6 [3.3, 
3.9] 
3.9 [3.6, 
4.3] 
4.2 [3.9, 
4.6] 
4.5 [4.2, 
4.9] 
4.9 [4.5, 
5.4] 
5.0 [5.0, 
6.0] 
6.7 [6.0, 
7.5] <0.0001 
Eosinophil 
Count   
0.1 [0.1, 
0.1] 
0.1 [0.1, 
0.2] 
0.1 [0.1, 
0.2] 
0.1 [0.1, 
0.2] 
0.1 [0.1, 
0.2] 
0.1 [0.1, 
0.2] 
0.2 [0.1, 
0.2] 
0.2 [0.1, 
0.3] 
0.2 [0.1, 
0.3] 
0.2 [0.1, 
0.3] <0.0001 
Basophil Count 
0.0 [0.0, 
0.0] 
0.0 [0.0, 
0.0] 
0.0 [0.0, 
0.0] 
0.0 [0.0, 
0.0] 
0.0 [0.0, 
0.0] 
0.0 [0.0, 
0.0] 
0.0 ]0.0, 
0.1] 
0.0 ]0.0, 
0.1] 
0.0 ]0.0, 
0.1] 
0.0 ]0.0, 
0.1] <0.0001 
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Table 2 Correlations (r) of leukocyte variables with each other 
WBC Lymphocyte count Lymphocyte % Monocyte count Monocyte % Neutrophil count Neutrophil % Eosinophil count Eosinophil % Basophil count 
Lymphocyte count 0.561 - - - - - - - - - 
Lymphocyte % -0.252 0.604 - - - - - - - - 
Monocyte count 0.479 0.307 -0.094 - - - - - - - 
Monocyte % -0.248 -0.115 0.092 0.673 - - - - - - 
Neutrophil count 0.902 0.222 -0.578 0.328 -0.344 - - - - - 
Neutrophil % 0.294 -0.506 -0.919 -0.107 -0.358 0.647 - - - - 
Eosinophil count 0.275 0.228 -0.003 0.255 0.061 0.139 -0.184 - - - 
Eosinophil % -0.068 0.030 0.088 0.092 0.160 -0.179 -0.305 0.900 - - 
Basophil count 0.266 0.205 -0.014 0.184 -0.015 0.197 -0.025 0.110 0.022 - 
Basophil% -0.027 0.059 0.088 0.070 0.097 -0.089 -0.161 0.066 0.080 0.665 
All r values significant at p<0.0001, except correlation of Eosinophil count with lymphocyte % (p=0.0243). 
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Table 3 Association of classical cardiovascular risk factors and leukocyte measures with all cause, cardiovascular and non-cardiovascular death. 
 Alive n=464797 
 
Dead n=13482 P-value vs alive  CVD mortality n=1377 P-value vs alive  Non-CVD mortality n=8987 
P-value 
vs alive 
Age (years) 56.4 ± 8.1  61.3 ± 6.6 <0.0001 62.2 ± 6.1 <0.0001 61.2 ± 6.7 <0.0001 
Male sex   211086 (45.4%)          8227 (61.0%) <0.0001  949 (68.9%) <0.0001  5005 (55.7%) <0.0001 
SBP (mmHg)   139.7 ± 19.6  143.9 ± 21.2 <0.0001 147.4 ± 22.7 <0.0001 143.2 ± 20.8 <0.0001 
BMI (kg/m2) 27.4 ± 4.8  28.1 ± 5.4 <0.0001 28.7 ± 5.5 <0.0001 27.6 ± 5.1 <0.0001 
Deprivation (score) -1.3 ± 3.1  -0.7 ± 3.4 <0.0001 -0.3 ± 3.5 <0.0001 -0.9 ± 3.3 <0.0001 
Smoking  <0.0001 <0.0001 <0.0001 
Non smoker 257211 (55.4%)  5103 (37.9%) 476 (34.6%) 3592    (40.0%) 
Ex-smoker 159641 (34.4%)  5665 (42.1%) 598 (43.5%) 3682    (41.0%) 
Current smoker 47464 (10.2%)  2696 (20.0%) 301 (21.9%) 1701    (19.0%) 
Ethnicity  <0.0001 0.27 <0.0001 
White 425732 (92.0%)  12590 (94.0%) 1257 (92.1%) 8446    (94.5%) 
South Asian 7359 (1.6%)  135 (1.0%) 27 (2.0%) 56     (0.6%) 
Black 7296 (1.6%)  107 (0.8%) 14 (1.0%) 68     (0.8%) 
Other 22253 (4.8%)  568 (4.2%) 67 (4.9%) 368    (4.1%) 
Baseline CVD 26228 (5.6%)  2286 (17.0%) 440 (32.0%) <0.0001 884    (9.8%) <0.0001 
Baseline diabetes 23454 (5.0%)  1786 (13.2%) <0.0001 276 (20.0%) <0.0001 855 (9.5%) <0.0001 
Family history of CVD 261530 (56.3%)  7958 (59.0%) <0.0001 882 (64.1%) <0.0001 5183    (57.7%) 0.0241 
Rheumatoid arthritis 5064 (1.1%)  288 (2.1%) <0.0001 40 (2.9%) <0.0001 161    (1.8%) <0.0001 
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Baseline CKD 676 (0.1%)  144 (1.1%) <0.0001 28 (2.0%) <0.0001 57     (0.6%) <0.0001 
Atrial fibrillation 3335 (0.7%)  227 (1.7%) <0.0001 40 (2.9%) <0.0001 83    (0.9%) 0.0429 
Other baseline illness 306924 (66.0%)  11275 (83.6%) <0.0001 1182 (85.8%) <0.0001 7339    (81.7%) <0.0001 
WBC (109/L) 6.6 [5.6, 7.8]  7.1 [5.9, 8.6] <0.0001 7.4 [6.2, 8.9] <0.0001 7.0 [5.8, 8.4] <0.0001 
Lymphocyte % 28.6 [24.0, 33.6]  26.0 [20.8, 31.6] <0.0001 25.7 [20.3, 31.6] <0.0001 26.6 [21.2, 32.0] <0.0001 
Lymphocytes (109/L)    1.9 [1.5, 2.3]  1.8 [1.4, 2.3] <0.0001 1.8 [1.5, 2.3] 0.071 1.8 [1.4, 2.3] <0.0001 
Monocyte% 6.8 [5.6, 8.2]  7.1 [5.7, 8.7] <0.0001 7.3 [5.7, 88] <0.0001 7.0 [5.6, 8.6] <0.0001 
Monocytes (109/L) 0.5 [0.4, 0.6]  0.5 [0.4, 0.6] <0.0001 0.5 [0.4, 0.7] <0.0001 0.5 [0.4, 0.6] <0.0001 
Neutrophil% 61.1 [55.6, 66.4]  63.2 [57.3, 69.2] <0.0001 63.5 [56.9, 69.4] <0.0001 62.9 [57.0, 68.8] <0.0001 
Neutrophils (109/L) 4.0 [3.3, 4.9]  4.5 [3.5, 5.6] <0.0001 4.7 [3.7, 5.8] <0.0001 4.4 [3.5, 5.4] <0.0001 
Eosinophil% 2.1 [1.4, 3.3]  2.1 [1.3, 3.2] <0.0001 2.1 [1.3, 3.2] 0.51 2.0 [1.3, 3.1] <0.0001 
Eosinophils (109/L) 0.1 [0.1, 0.2]  0.1 [0.1, 0.2] <0.0001 0.2 [0.1, 0.2] <0.0001 0.1 [0.1, 0.2] 0.0158 
Basophil% 0.4 [0.3, 0.7]  0.4 [0.3, 0.7] 0.0.15 0.4 [0.3, 0.7] 0.69 0.4 [0.3, 0.7] 0.0940 
Basophils (109/L) 0.0 [0.0, 0.0]  0.0 [0.0, 0.1] 0.005 0.0 [0.0, 0.1] 0.45 0.0 [0.0, 0.1] <0.0001 
 
 
21 
 
Figure A 
 
22 
 
Figure B 
 
23 
 
Figure C 
 
24 
 
Figure D 
 
